Table 3.
Trial | Treatments | Subtype | n | End points |
---|---|---|---|---|
Miyashita et al. (41) |
|
TNBC | 131 |
|
Dieci et al. (42) |
|
TNBC | 278 |
|
Loi et al. (43) |
|
TNBC | 111 | A strong positive linear association of TILs in NAC-treated specimens was observed with RFS (P = 0.0001, relative risk reduction of 3.4% for each 1% of TILs) and OS (P = 0.0016; relative risk reduction of 2.8% for each% of TILs) |
Total patients | 520 |
DFS, disease-free survival; MFS, metastases-free survival, NAC, neoadjuvant chemotherapy; OS, overall survival; RFS, recurrence free survival; sTIL, stromal TIL; TNBC, triple-negative breast cancer.